Illumina Inc. has announced a collaboration and strategic investment with MyOme, a genomics innovation and risk modeling company. The partnership aims to advance MyOme's Proactive Health (MPH) Trial, a large-scale clinical trial designed to demonstrate the benefits of using whole-genome sequencing combined with MyOme's AI-integrated risk models for early detection and prevention of common, chronic conditions, cancers, and rare diseases. Illumina's leading sequencing technology will be integrated with MyOme's advanced bioinformatics and risk models to deliver improved patient outcomes and significant healthcare cost savings. The collaboration also supports the expansion of MyOme's diagnostic products, including proactive health and rare disease tests, with the goal of providing more accurate, ancestry-relevant risk assessments for a wide range of diseases.